Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19

Objective

To investigate supplementation of the combined metabolic activators (CMA), consisting of L-serine, N-acetyl-L-cysteine (NAC), NR, and L-carnitine tartrate for the treatment of patients with COVID-19.

Study Design

Phase II: Randomized, open-label, placebo-controlled study in 93 patients

Phase III: Randomized, double-blind, placebo-controlled study in 309 COVID-19 patients

Dose

2000 mg

“Combined metabolic activators” or “CMA,” in combination with hydroxychloroquine (HCQ) or favipiravir (FP) for the treatment of patients with COVID-19. The CMA was administered twice per day for 14 days, and each dose consisted of 3.73g L-carnitine tartrate, 1g NR, 12.35g serine, and 2.55g N-acetyl-L-cysteine.

Duration

2 weeks

Key Outcomes

  • After 14 days, CMA supplementation significantly reduced recovery time compared to placebo group in phase II (6.6 vs 9.3 days, respectively), as well as in phase III (5.7 vs. 9.2 days, respectively).

  • CMA supplementation also improved liver health and markers of inflammation in COVID-19 patients.

Clinical, Inflammation/Immune HealthANAD Staff